论文部分内容阅读
Unlike in the US and EU where modern pharmaceutical research and development have matured for more than 150 years, in China, research and development (R&D) has been in the field for 15 to 20 years.Moreover, multi-national companies (MNCs) have focused on procuring registered drugs from developed nations to China.Therefore, the R&D system established in China addresses the immediate regulatory requirements (necessary clinical trials) rather than future innovations.MNCs have also utilized low-cost structures in China to address some of the discovery aspects of pharmaceutical R&D, such as medicinal chemistry and biological analysis; MNCs have also participated in few global trials.This history has further improved Chinese regulatory policies.For example, one should obtain a Certificate of Pharmaceutical Products (COPP) from a developed country before CTAs for imported medicines could be filed.These initiatives have provided the basis for pharmaceutical R&D of MNCs in China.Such basis also involves the participation in only small parts of the R&D process.Considering that China has approximately one fourth of the worlds population and 60% of the population in Asia-Pacific, we believe that a partial participation of R&D does not serve the regions precise needs to have market-and patient-appropriate medicines for the treatment of diseases relevant to billions of Chinese and other individuals in China, where patients reside.